Ari Bitnun1, E Ann Yeh2. 1. Division of Infectious Diseases, The Hospital for Sick Children and Department of Pediatrics, University of Toronto, Toronto, ON, M5G 1X8, Canada. ari.bitnun@sickkids.ca. 2. Division of Neurology, The Hospital for Sick Children and Department of Pediatrics, Division of Neurosciences and Mental Health, SickKids Research Institute, University of Toronto, Toronto, Canada.
Abstract
PURPOSE OF REVIEW: The focus of this review is on enterovirus (EV)-associated acute flaccid paralysis (AFP) due to spinal cord anterior horn cell disease. Emphasis is placed on the epidemiology, pathogenesis, diagnosis, treatment, and outcome of AFP caused by polioviruses, vaccine-derived polioviruses, EV-D68, and EV-A71. RECENT FINDINGS: Since the launch of The Global Polio Eradication Initiative in 1988, the worldwide incidence of polio has been reduced by 99.9%, with small numbers of poliomyelitis cases being reported only in Afghanistan, Pakistan, and Nigeria. With the planned phaseout of oral polio vaccine, vaccine-associated poliomyelitis is also expected to be eliminated. In their place, other EVs, chiefly EV-D68 and EV-A71, have emerged as the principal causes of AFP. There is evidence that the emergence of EV-D68 as a cause of severe respiratory disease and AFP was due to recent genetic virus evolution. Antiviral medications targeting EV-D68, EV-A71, and other EVs will likely be available in the near future. An effective EV-A71 vaccine has been developed, and preliminary investigations suggest an EV-D68 vaccine could be on the horizon. The eradication of poliomyelitis and vaccine-associated poliomyelitis is near, after which other EVs, presently EV-D68 and EV-A71, will be the principle viral causes of AFP. Moving forward, it is essential that EV outbreaks, in particular those associated with neurologic complications, be investigated carefully and the causal strains identified, so that treatment and prevention efforts can be rapidly developed and implemented.
PURPOSE OF REVIEW: The focus of this review is on enterovirus (EV)-associated acute flaccid paralysis (AFP) due to spinal cord anterior horn cell disease. Emphasis is placed on the epidemiology, pathogenesis, diagnosis, treatment, and outcome of AFP caused by polioviruses, vaccine-derived polioviruses, EV-D68, and EV-A71. RECENT FINDINGS: Since the launch of The Global Polio Eradication Initiative in 1988, the worldwide incidence of polio has been reduced by 99.9%, with small numbers of poliomyelitis cases being reported only in Afghanistan, Pakistan, and Nigeria. With the planned phaseout of oral polio vaccine, vaccine-associated poliomyelitis is also expected to be eliminated. In their place, other EVs, chiefly EV-D68 and EV-A71, have emerged as the principal causes of AFP. There is evidence that the emergence of EV-D68 as a cause of severe respiratory disease and AFP was due to recent genetic virus evolution. Antiviral medications targeting EV-D68, EV-A71, and other EVs will likely be available in the near future. An effective EV-A71 vaccine has been developed, and preliminary investigations suggest an EV-D68 vaccine could be on the horizon. The eradication of poliomyelitis and vaccine-associated poliomyelitis is near, after which other EVs, presently EV-D68 and EV-A71, will be the principle viral causes of AFP. Moving forward, it is essential that EV outbreaks, in particular those associated with neurologic complications, be investigated carefully and the causal strains identified, so that treatment and prevention efforts can be rapidly developed and implemented.
Authors: J A Maloney; D M Mirsky; K Messacar; S R Dominguez; T Schreiner; N V Stence Journal: AJNR Am J Neuroradiol Date: 2014-11-20 Impact factor: 3.825
Authors: Rafal Tokarz; Cadhla Firth; Shabir A Madhi; Stephen R C Howie; Winfred Wu; Amadou Alpha Sall; Saddef Haq; Thomas Briese; W Ian Lipkin Journal: J Gen Virol Date: 2012-06-13 Impact factor: 3.891
Authors: Sanet Torres-Torres; Angela L Myers; J Michael Klatte; Eric E Rhoden; M Steven Oberste; Marc S Collett; Russell J McCulloh Journal: Pediatr Infect Dis J Date: 2015-01 Impact factor: 2.129
Authors: James J Sejvar; Adriana S Lopez; Margaret M Cortese; Eyal Leshem; Daniel M Pastula; Lisa Miller; Carol Glaser; Anita Kambhampati; Kayoko Shioda; Negar Aliabadi; Marc Fischer; Nicole Gregoricus; Robert Lanciotti; W Allan Nix; Senthilkumar K Sakthivel; D Scott Schmid; Jane F Seward; Suxiang Tong; M Steven Oberste; Mark Pallansch; Daniel Feikin Journal: Clin Infect Dis Date: 2016-06-17 Impact factor: 9.079
Authors: J J Edwin; F Reyes Domingo; T F Booth; T Mersereau; D M Skowronski; C Chambers; K Simmonds; A N Scott; A L Winter; A Peci; J Gubbay; S J Drews; M Krajden; T Karnauchow; M Smieja; S Rempel; M Murti; S Pollock; R Gustafson; D Hoyano; S Allison; S Fathima; K Pabbaraju; S Wong; R Tellier; G Tipples; R R Gad; S N Mukhi; Y Jafari; E Grudeski; A McDermid; T Wong Journal: Can Commun Dis Rep Date: 2015-02-20